Switch theme
Sign up to access all valuation multiples
Harvard Apparatus Regenerative Technology Inc is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastrointestinal system and the airway resulting from cancer, trauma, or birth defects. The company's technology is based on its proprietary cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs.
2012
18
LTM Revenue n/a
LTM EBITDA n/a
$43.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Harvard Apparatus has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Harvard Apparatus achieved revenue of $0.1M and an EBITDA of -$8.8M.
Harvard Apparatus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Harvard Apparatus valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $0.1M | n/a | n/a | XXX |
| Gross Profit | n/a | n/a | $0.1M | XXX | XXX |
| Gross Margin | NaN% | 0% | NaN% | XXX | XXX |
| EBITDA | -$6.0M | -$8.8M | n/a | n/a | XXX |
| EBITDA Margin | -Infinity% | -8541% | NaN% | NaN% | XXX |
| Net Profit | -$8.0M | -$6.1M | -$8.9M | XXX | XXX |
| Net Margin | -Infinity% | -5896% | NaN% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Harvard Apparatus's stock price is $3.
Harvard Apparatus has current market cap of $46.5M, and EV of $43.2M.
See Harvard Apparatus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $43.2M | $46.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Harvard Apparatus has market cap of $46.5M and EV of $43.2M.
Harvard Apparatus's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Harvard Apparatus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Harvard Apparatus and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $43.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHarvard Apparatus's NTM/LTM revenue growth is n/a
Harvard Apparatus's revenue per employee for the last fiscal year averaged $6K, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Harvard Apparatus's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Harvard Apparatus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Harvard Apparatus and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $6K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 285% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5547% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2973% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 8805% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Harvard Apparatus acquired XXX companies to date.
Last acquisition by Harvard Apparatus was XXXXXXXX, XXXXX XXXXX XXXXXX . Harvard Apparatus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Harvard Apparatus founded? | Harvard Apparatus was founded in 2012. |
| Where is Harvard Apparatus headquartered? | Harvard Apparatus is headquartered in United States of America. |
| How many employees does Harvard Apparatus have? | As of today, Harvard Apparatus has 18 employees. |
| Is Harvard Apparatus publicy listed? | Yes, Harvard Apparatus is a public company listed on PINX. |
| What is the stock symbol of Harvard Apparatus? | Harvard Apparatus trades under HRGN ticker. |
| When did Harvard Apparatus go public? | Harvard Apparatus went public in 2013. |
| Who are competitors of Harvard Apparatus? | Similar companies to Harvard Apparatus include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Harvard Apparatus? | Harvard Apparatus's current market cap is $46.5M |
| Is Harvard Apparatus profitable? | Yes, Harvard Apparatus is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
